Roche announced the U.S. Food and Drug Administration approval of the cobas Malaria test for use on the cobas 6800/8800 Systems. This approved test can aid healthcare professionals in reducing potential risks of patient infection from transfused blood products. The cobas Malaria test provides a highly sensitive and specific solution to help ensure that infected blood units are removed from the blood supply. The cobas Malaria molecular test screens whole blood samples for the five main species of Plasmodium parasites that are known to cause human infection. The potential value of a molecular donor screening test for malaria is to improve both blood safety and availability. The test is intended for use in screening blood, organ and tissue donors. The test will be available in the United States at the end of Q2 2024. Approval in CE-marked countries is anticipated later this year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
- Rocheâs mixed myasthenia gravis data sending these stocks in opposite directions
- Tourmaline Bio might see weakness today after Roche MG data, says Truist
- Immunovant rallies after Chugai myasthenia gravis study failure
- Tourmaline Bio sinks after Chugai myasthenia gravis study failure